Showing 13 to 24 of 92 results
VRTX Earnings: 58% Probability of Positive One-Day Return, Trend Weakening
Vertex Pharmaceuticals (VRTX) reports earnings on August 4, 2025; over the past five years, post-earnings announcements show a 58% probability of positive one-day returns, with a median increase of 3.0%, but this trend weakens to 50% in the last three years.
VRTX Earnings: 58% Probability of Positive One-Day Return, Trend Weakening
Vertex Pharmaceuticals (VRTX) reports earnings on August 4, 2025; over the past five years, post-earnings announcements show a 58% probability of positive one-day returns, with a median increase of 3.0%, but this trend weakens to 50% in the last three years.
Progress
48% Bias Score
NeuroScientific Appoints CMO, Share Price Soars 371%
NeuroScientific Biopharmaceuticals appointed Dr. Catherine Cole as its chief medical officer, boosting its share price by 371 percent since June and accelerating development of its StemSmart stem cell technology for treating severe immune complications; interim results from a Crohn's disease trial a...
NeuroScientific Appoints CMO, Share Price Soars 371%
NeuroScientific Biopharmaceuticals appointed Dr. Catherine Cole as its chief medical officer, boosting its share price by 371 percent since June and accelerating development of its StemSmart stem cell technology for treating severe immune complications; interim results from a Crohn's disease trial a...
Progress
56% Bias Score
Sanofi to Acquire Vicebio for $1.6 Billion, Expanding Vaccine Portfolio
French pharmaceutical giant Sanofi is acquiring British biotech firm Vicebio for up to $1.6 billion, gaining access to its novel combination vaccine candidate for RSV and hMPV, and its 'Molecular Clamp' technology, with the deal expected to close in the fourth quarter of 2025.
Sanofi to Acquire Vicebio for $1.6 Billion, Expanding Vaccine Portfolio
French pharmaceutical giant Sanofi is acquiring British biotech firm Vicebio for up to $1.6 billion, gaining access to its novel combination vaccine candidate for RSV and hMPV, and its 'Molecular Clamp' technology, with the deal expected to close in the fourth quarter of 2025.
Progress
32% Bias Score
Colossal Biosciences to 'De-Extinct' New Zealand's Giant Moa
Colossal Biosciences plans to 'de-extinct' New Zealand's giant moa, extinct for 600 years, by collaborating with the Ngāi Tahu Research Centre to analyze ancient DNA and restore potential habitats, sparking debate about conservation priorities and genetic engineering.
Colossal Biosciences to 'De-Extinct' New Zealand's Giant Moa
Colossal Biosciences plans to 'de-extinct' New Zealand's giant moa, extinct for 600 years, by collaborating with the Ngāi Tahu Research Centre to analyze ancient DNA and restore potential habitats, sparking debate about conservation priorities and genetic engineering.
Progress
44% Bias Score
Republican Healthcare Bill to Leave 11.8 Million Uninsured by 2034
The Republican domestic policy bill, if passed, will cause 11.8 million more Americans to be uninsured by 2034 due to over $1 trillion in cuts to Medicaid and other healthcare programs, disproportionately impacting low-income individuals and rural healthcare systems.
Republican Healthcare Bill to Leave 11.8 Million Uninsured by 2034
The Republican domestic policy bill, if passed, will cause 11.8 million more Americans to be uninsured by 2034 due to over $1 trillion in cuts to Medicaid and other healthcare programs, disproportionately impacting low-income individuals and rural healthcare systems.
Progress
48% Bias Score
Plastic Waste Converted into Paracetamol Using Genetically Modified Bacteria
Scientists at the University of Edinburgh have developed a method to convert plastic waste into paracetamol using genetically modified E. coli bacteria, achieving a 90% conversion rate in under 24 hours at room temperature, reducing carbon emissions and offering a sustainable alternative to traditio...
Plastic Waste Converted into Paracetamol Using Genetically Modified Bacteria
Scientists at the University of Edinburgh have developed a method to convert plastic waste into paracetamol using genetically modified E. coli bacteria, achieving a 90% conversion rate in under 24 hours at room temperature, reducing carbon emissions and offering a sustainable alternative to traditio...
Progress
44% Bias Score
Edible Medicines: Growing Peptides in Plants
Australian researchers are using a $1.2 million grant to develop edible medicines by growing peptides with pain-relieving, cholesterol-lowering, and appetite-suppressing properties in plants, using a robot-powered plant factory in Sydney and aiming for human trials in three years.
Edible Medicines: Growing Peptides in Plants
Australian researchers are using a $1.2 million grant to develop edible medicines by growing peptides with pain-relieving, cholesterol-lowering, and appetite-suppressing properties in plants, using a robot-powered plant factory in Sydney and aiming for human trials in three years.
Progress
56% Bias Score
Sanofi Acquires Vicebio for €980 Million, Expanding Respiratory Vaccine Portfolio
Sanofi is acquiring British biotech firm Vicebio for €980 million plus potential milestone payments, gaining access to a combined hMPV/RSV vaccine and Molecular Clamp technology to accelerate vaccine development and address global respiratory infections.
Sanofi Acquires Vicebio for €980 Million, Expanding Respiratory Vaccine Portfolio
Sanofi is acquiring British biotech firm Vicebio for €980 million plus potential milestone payments, gaining access to a combined hMPV/RSV vaccine and Molecular Clamp technology to accelerate vaccine development and address global respiratory infections.
Progress
44% Bias Score
Yeast-Based Infant Formula Aims to Replicate Breast Milk
Australian biotech company All G is developing a yeast-based infant formula aiming to replicate key components of human breast milk, expecting market availability by 2028, while facing scientific and regulatory challenges.
Yeast-Based Infant Formula Aims to Replicate Breast Milk
Australian biotech company All G is developing a yeast-based infant formula aiming to replicate key components of human breast milk, expecting market availability by 2028, while facing scientific and regulatory challenges.
Progress
64% Bias Score
\£10 Million Grant Funds Project to Create Synthetic Human Chromosome
The Synthetic Human Genome Project (SynHG) received \£10 million to create a synthetic human chromosome within 5-10 years, aiming to advance genome synthesis technology for disease treatment and research, while raising ethical concerns about potential misuse.
\£10 Million Grant Funds Project to Create Synthetic Human Chromosome
The Synthetic Human Genome Project (SynHG) received \£10 million to create a synthetic human chromosome within 5-10 years, aiming to advance genome synthesis technology for disease treatment and research, while raising ethical concerns about potential misuse.
Progress
16% Bias Score
Wellcome Trust Funds Controversial Synthetic Human Genome Project
The Wellcome Trust has funded a £10 million project to synthesize human DNA, aiming to accelerate treatments for incurable diseases but raising ethical concerns about potential misuse for creating enhanced humans or biological weapons.
Wellcome Trust Funds Controversial Synthetic Human Genome Project
The Wellcome Trust has funded a £10 million project to synthesize human DNA, aiming to accelerate treatments for incurable diseases but raising ethical concerns about potential misuse for creating enhanced humans or biological weapons.
Progress
20% Bias Score
E. coli Bacteria Convert Plastic Waste into Paracetamol
Scientists at the University of Edinburgh used E. coli bacteria to convert PET plastic into paracetamol, a process mimicking the Lossen rearrangement reaction and offering a more sustainable alternative to traditional fossil fuel-based manufacturing, as published in Nature.
E. coli Bacteria Convert Plastic Waste into Paracetamol
Scientists at the University of Edinburgh used E. coli bacteria to convert PET plastic into paracetamol, a process mimicking the Lossen rearrangement reaction and offering a more sustainable alternative to traditional fossil fuel-based manufacturing, as published in Nature.
Progress
20% Bias Score
Showing 13 to 24 of 92 results